CDK 4/6 inhibitors have transformed the treatment landscape for patients with early and metastatic hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer, offering significant improvements in progression-free survival and overall outcomes, especially when combined with hormone therapy. Despite their demonstrated efficacy, these therapies can be associated with treatment-related adverse events, including gastrointestinal (GI) symptoms, neutropenia, and anemia, which require careful management to ensure adherence and preserve quality of life. Managing these therapies comes with challenges, particularly in the community setting where the majority of patients receive their care. Clinicians must navigate the evolving landscape of HR+ breast cancer while ensuring tolerability, adherence, and optimal outcomes.
This program aims to provide oncology professionals with evidence-based strategies to optimize the use of CDK 4/6 inhibitors across the breast cancer continuum. By addressing both early and metastatic disease settings, the program emphasizes the importance of dose adjustments to manage adverse events effectively without compromising efficacy. It also highlights the critical role of multidisciplinary care coordination in balancing patient outcomes with quality of life.
Tailored for oncology clinicians, the program offers practical insights to enhance patient care through proactive management of treatment-related side effects, streamlined care coordination, and comprehensive patient and caregiver education.
Objectives
Contact Us
For more information on this project, please contact the ACCC Provider Education department.
This spotlight examines the dynamic role of a clinical pharmacy specialist at Miami Cancer Institute (MCI), part of Baptist Health South Florida, in the management of patients with breast cancer treated with oral therapies such as CDK4/6 inhibitors. MCI operates within a hybrid academic-community care model, offering access to subspecialized clinicians, clinical researchers, and genomic scientists, many of whom bring experience from leading cancer centers nationwide.
This project is supported by Lilly.
